Pembro Provides DFS Benefit in Early NSCLC

Adjuvant pembrolizumab significantly improved disease-free survival (DFS) compared to placebo in patients who had undergone complete resection, according to findings from the phase 3 PEARLS study.
Medscape Medical News

source https://www.medscape.com/viewarticle/971764?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?